ct 1

CT-1 is a DNA minor groove ligand and causes p53-dependent breast cancer cell apoptosis.

CT1-3 is a potent anti-cancer agent. CT1-3 regulates the JNK/Bcl-2/Bax/XIAP pathway, which induces mitochondria-mediated apoptosis. CT1-3 regulates the E-cadherin/Snail axis to inhibit epithelial mesenchymal transition (EMT) potentials in human cancer cells (HCCs) and suppresses tumourigenesis. CT1-3 has anti-tumour effects in mouse models and does not show significant hepatotoxicity or nephrotoxicity.

1. Citric acid (Citro) (1-2 g kg) can decrease brain lipid peroxidation and inflammation, liver damage, and DNA fragmentation. 2. Citric acid denture cleansers can reduce C. albicans biofilm accumulation and cell viability. However, this CT did not prevent biofilm recolonization.

Regdanvimab (CT-P59) is a human monoclonal antibody targeting the receptor-binding domain of the SARS-CoV-2 spike protein, inhibiting the virus's cell entry by blocking its interaction with the ACE2 receptor. It is utilized in COVID-19 research [1].

Firivumab (CT-P22; CT120), a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA), demonstrates neutralization capabilities against multiple strains including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. It has also shown to protect mice from the H1N1 virus [1] [2] [3].

OK2, a specific inhibitor of the CCN2 EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2 and holds potential for research on kidney fibrosis and chronic kidney disease [1].

Pegdinetanib (BMS-844203; CT-322) is a selective inhibitor targeting VEGFR-2 (VEGFR), with dissociation constants (Kd) of 11 nM and 250 nM and half-maximal inhibitory concentrations (IC50) of 16 nM and 240 nM for human and murine VEGFR-2, respectively, and shows no affinity for VEGFR-1 or VEGFR-3, demonstrating antitumor activity [1].

Sigma-2 Radioligand 1 (compound 1) serves as a selective Sigma-2 ligand, demonstrating favorable biodistribution in mice and robust in vivo activity in rats. The [18F] modified version of Sigma-2 Radioligand 1 enhances the visualization of tumors in micro-PET CT imaging by providing high tumor uptake and an impressive tumor-to-background ratio. Additionally, experiments confirm that this compound binds with high specificity to U87MG glioma xenografts [1].

Enzyme-IN-1 (compound 1), a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases, specifically targets and inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. This compound may possess potential anti-inflammatory properties [1].

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].

Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt β-catenin pathway, and can be used to study hepatocellular carcinoma.

SSI-4 is a Stearoyl CoA desaturase 1 (SCD1) inhibitor that can be labeled with carbon-11 (11C) for use as a ligand in small animal in vivo PET/CT imaging studies of SCD1 [1].

Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic malignancies [1].

Citric Acid Monohydrate is a tricarboxylic acid found in citrus fruits. Citric acid is used as an excipient in pharmaceutical preparations due to its antioxidant properties. It maintains stability of active ingredients and is used as a preservative.

Triammonium citrate, also known as citric acid triammonium, results from the reaction between citric acid and ammonia at a 1:3 molar ratio. This compound serves as a carbon source for the synthesis of carbon quantum dots (CDs). The presence of higher nitrogen content in triammonium citrate may enhance nitrogen-based functional groups in CDs, thereby improving emission-color tunability [1] [2].

Citric acid trilithium salt tetrahydrate (Lithium citrate tribasic tetrahydrate) , the active component of Lithium, is a medicine used in the therapy of psychiatric disease. It has shown the effects of signaling pathways and metabolic in the brain based on the particular disease and clinical condition model. According to the reports, Citric acid trilithium salt tetrahydrate was used as a mood stabilizer when treating bipolar mood disorders (BD) and lower the risk of self-harm in BD patient. In addition,Citric acid trilithium salt tetrahydrate has been the choice drug in the therapy of acute manic episodes.Citric acid trilithium salt tetrahydrate also could dissolve uric acid crystals in urine achieved from patients with gout. Besides,Citric acid trilithium salt tetrahydrate have some dose-dependent side-effects. The the main side-effects of Lithium Citrate is the tendency to inhibit the prostatic acid phosphatase enzyme (PAP), which result in the accumulation of PAP.

Sodium citrate dihydrate (Trisodium citrate dihydrate) is an anticoagulant, and also used as a buffer and food preservatives.